Amphastar P (AMPH)

Currency in USD
23.18
-0.66(-2.77%)
Closed·
22.91-0.27(-1.16%)
·

AMPH Comments

pro badge
Great time to keep accumulating. With projected revenue growth between 8% and 12% for 2026 and a steady share buyback program, I’m forecasting an EPS in the $3.60 - $3.80 range. This outlook assumes a conservative uptake for the AMP-007 launch mid-year, which I highly doubt will be the case. There are currently no real generic alternatives in a massive market where GSK has mismanaged its monopoly; payers and insurers are fed up with GSK's practices and are eager for a viable alternative. Amphastar is perfectly positioned to capture significant market share immediately. It’s hard to see a scenario where the stock doesn’t justify a $40 - $45 price target by year-end 2026. If the new launches gain traction as expected, I see a clear path toward $50 - $60 over the next 12 to 18 months. At current levels, the undervaluation is blatant.
Good management (insiders are aligned). High margins and healthy financial balance sheet so that means a profitability company. And even on top of that, really low price ratios.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.